Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib vs Sunitinib in Advanced GIST After Imatinib
NCT03673501Phase 3Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Sep 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 22
01
Overview
A Phase 3 trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Started Feb 2019; status: active, not recruiting.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03673501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673501.